INTRODUCTION: Alzheimer's disease is a multifactorial syndrome, which is not yet fully understood, causing memory loss, dementia, and, ultimately, death. Acetylcholinesterase inhibitors are the mainstay drugs that are used in disease-symptomatic treatment. In this work, we report a new synthetic route yielding sugar amides as low to moderate acetylcholinesterase inhibitors. METHOD: Commercially available diacetone glucose was converted into perbenzyl D-glucono-1,4-lactone, which reacted with aromatic or aliphatic amines to afford the corresponding new amides in a high isolated yield. Docking studies of the most promising hydroxybutylamide and benzylamide were performed to assign binding interactions with acetylcholinesterase and determine the key features for bioactivity. RESULT: The inhibitors are accommodated in enzyme gorge, blocking the access to Ser203 mainly due to Pi-Pi stacking interactions of sugar benzyl groups with the aromatic gorge residues, Tyr337 and Tyr341 for both inhibitors and Trp439 only for the hydroxybutylamide. CONCLUSION: Bonding is also significant through sugar interaction with the residues Tyr124 and Ser125-OH in both inhibitors. Flexibility of these open-chain structures seems to be quite relevant for the observed binding to acetylcholinesterase.
        
Related information
Citations formats
Goncalves-Pereira R, Figueiredo JA, Lucas SD, Garcia-Moreno MI, Mellet CO, Rauter AP, Ismael MI (2022) Synthesis, Biological Evaluation, and Docking Studies of Open-chain Carbohydrate Amides as Acetylcholinesterase Inhibitors Med Chem
Goncalves-Pereira R, Figueiredo JA, Lucas SD, Garcia-Moreno MI, Mellet CO, Rauter AP, Ismael MI (2022) Med Chem